Malignant Transformation Involving CXXC4 Mutations Identified in a Leukemic Progression Model of Severe Congenital Neutropenia

To investigate how the combination of CSF3 therapy and CSF3R and RUNX1 mutations contributes to acute myeloid leukemia (AML) development, researchers make use of mouse models, severe congenital neutropenia (SCN)-derived iPSCs, and SCN and SCN-AML patient samples.